By the end of 2020, the cumulative incidence of COVID-19 diagnoses was 7.7% and 15.8% among individuals with CKD and those undergoing dialysis, respectively.
In a study of patients receiving dialysis, 1 in 5 patients fully vaccinated against the SARS-CoV-2 coronavirus, which causes COVID-19, had undetectable levels of antibodies 5 to 6 months after vaccination.
Atrasentan lowers the risk for a composite of kidney failure, doubling of serum creatinine, or kidney death consistently across subgroups of urinary albumin-creatinine ratio and estimated glomerular filtration rate.
A sex-specific difference in dialysis initiation emerged in a study of participants in the multinational Chronic Kidney Disease Outcomes and Practice Patterns Study.
